Which has preferable valuation & earnings, IBRX or KARD?

Kardigan has lower revenue, but higher earnings than ImmunityBio. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ImmunityBio $113.29M 77.18 -$351.40M -$0.97 N/A Kardigan N/A N/A N/A N/A N/A

Is IBRX or KARD more profitable?

Kardigan has a net margin of 0.00% compared to ImmunityBio's net margin of -598.55%. Company Net Margins Return on Equity Return on Assets ImmunityBio -598.55% N/A -51.65% Kardigan N/A N/A N/A

Does the media favor IBRX or KARD?

In the previous week, ImmunityBio had 3 more articles in the media than Kardigan. MarketBeat recorded 7 mentions for ImmunityBio and 4 mentions for Kardigan. ImmunityBio's average media sentiment score of 0.95 beat Kardigan's score of 0.23 indicating that ImmunityBio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ImmunityBio 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Kardigan 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation & earnings, RYTM or KARD?

Kardigan has lower revenue, but higher earnings than Rhythm Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Rhythm Pharmaceuticals $189.76M 40.40 -$196.54M -$3.11 N/A Kardigan N/A N/A N/A N/A N/A

Does the media prefer RYTM or KARD?

In the previous week, Rhythm Pharmaceuticals had 9 more articles in the media than Kardigan. MarketBeat recorded 13 mentions for Rhythm Pharmaceuticals and 4 mentions for Kardigan. Rhythm Pharmaceuticals' average media sentiment score of 1.36 beat Kardigan's score of 0.23 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rhythm Pharmaceuticals 9 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kardigan 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings and valuation, KARD or TGTX?

TG Therapeutics has higher revenue and earnings than Kardigan. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kardigan N/A N/A N/A N/A N/A TG Therapeutics $799.54M 10.54 $447.18M $2.74 20.08

Does the media refer more to KARD or TGTX?

In the previous week, TG Therapeutics had 9 more articles in the media than Kardigan. MarketBeat recorded 13 mentions for TG Therapeutics and 4 mentions for Kardigan. TG Therapeutics' average media sentiment score of 1.12 beat Kardigan's score of 0.23 indicating that TG Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kardigan 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral TG Therapeutics 6 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, KARD or ORKA?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kardigan N/A N/A N/A N/A N/A Oruka Therapeutics N/A N/A -$105.43M -$2.03 N/A

Is KARD or ORKA more profitable?

Kardigan's return on equity of 0.00% beat Oruka Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Kardigan N/A N/A N/A Oruka Therapeutics N/A -21.65% -20.88%

Does the media favor KARD or ORKA?

In the previous week, Oruka Therapeutics had 4 more articles in the media than Kardigan. MarketBeat recorded 8 mentions for Oruka Therapeutics and 4 mentions for Kardigan. Oruka Therapeutics' average media sentiment score of 1.29 beat Kardigan's score of 0.23 indicating that Oruka Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kardigan 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Oruka Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, KARD or CGON?

Kardigan has higher earnings, but lower revenue than CG Oncology. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kardigan N/A N/A N/A N/A N/A CG Oncology $4.04M 1,720.58 -$160.99M -$2.69 N/A

Is KARD or CGON more profitable?

Kardigan has a net margin of 0.00% compared to CG Oncology's net margin of -3,602.68%. Kardigan's return on equity of 0.00% beat CG Oncology's return on equity. Company Net Margins Return on Equity Return on Assets Kardigan N/A N/A N/A CG Oncology -3,602.68% -25.20% -23.98%

Does the media prefer KARD or CGON?

In the previous week, CG Oncology had 2 more articles in the media than Kardigan. MarketBeat recorded 6 mentions for CG Oncology and 4 mentions for Kardigan. CG Oncology's average media sentiment score of 1.05 beat Kardigan's score of 0.23 indicating that CG Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kardigan 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral CG Oncology 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Kardigan (KARD) Competitors

$21.18 +0.26 (+1.24%)

As of 04:00 PM Eastern

Compare

KARD vs. IBRX, RYTM, TGTX, ORKA, and CGON

Should you buy Kardigan stock or one of its competitors? Kardigan's main competitors and comparable companies include ImmunityBio (IBRX), Rhythm Pharmaceuticals (RYTM), TG Therapeutics (TGTX), Oruka Therapeutics (ORKA), and CG Oncology (CGON). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Kardigan compare to ImmunityBio?

ImmunityBio (NASDAQ:IBRX) and Kardigan (NASDAQ:KARD) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, analyst recommendations, media sentiment, risk, earnings and profitability.

Kardigan has lower revenue, but higher earnings than ImmunityBio.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmunityBio	$113.29M	77.18	-$351.40M	-$0.97	N/A
Kardigan	N/A	N/A	N/A	N/A	N/A

8.6% of ImmunityBio shares are owned by institutional investors. 66.1% of ImmunityBio shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, ImmunityBio had 3 more articles in the media than Kardigan. MarketBeat recorded 7 mentions for ImmunityBio and 4 mentions for Kardigan. ImmunityBio's average media sentiment score of 0.95 beat Kardigan's score of 0.23 indicating that ImmunityBio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ImmunityBio	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Kardigan	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Kardigan has a net margin of 0.00% compared to ImmunityBio's net margin of -598.55%.

Company	Net Margins	Return on Equity	Return on Assets
ImmunityBio	-598.55%	N/A	-51.65%
Kardigan	N/A	N/A	N/A

ImmunityBio presently has a consensus target price of $14.20, suggesting a potential upside of 72.12%. Kardigan has a consensus target price of $42.25, suggesting a potential upside of 99.48%. Given Kardigan's stronger consensus rating and higher probable upside, analysts clearly believe Kardigan is more favorable than ImmunityBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmunityBio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Kardigan	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80

Summary

ImmunityBio beats Kardigan on 6 of the 10 factors compared between the two stocks.

How does Kardigan compare to Rhythm Pharmaceuticals?

Rhythm Pharmaceuticals (NASDAQ:RYTM) and Kardigan (NASDAQ:KARD) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings, media sentiment and profitability.

Rhythm Pharmaceuticals currently has a consensus target price of $142.44, suggesting a potential upside of 27.32%. Kardigan has a consensus target price of $42.25, suggesting a potential upside of 99.48%. Given Kardigan's stronger consensus rating and higher possible upside, analysts plainly believe Kardigan is more favorable than Rhythm Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rhythm Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.78
Kardigan	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80

In the previous week, Rhythm Pharmaceuticals had 9 more articles in the media than Kardigan. MarketBeat recorded 13 mentions for Rhythm Pharmaceuticals and 4 mentions for Kardigan. Rhythm Pharmaceuticals' average media sentiment score of 1.36 beat Kardigan's score of 0.23 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rhythm Pharmaceuticals	9 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kardigan	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Kardigan has a net margin of 0.00% compared to Rhythm Pharmaceuticals' net margin of -85.59%. Kardigan's return on equity of 0.00% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rhythm Pharmaceuticals	-85.59%	-159.87%	-44.00%
Kardigan	N/A	N/A	N/A

Kardigan has lower revenue, but higher earnings than Rhythm Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rhythm Pharmaceuticals	$189.76M	40.40	-$196.54M	-$3.11	N/A
Kardigan	N/A	N/A	N/A	N/A	N/A

Summary

Kardigan beats Rhythm Pharmaceuticals on 5 of the 9 factors compared between the two stocks.

How does Kardigan compare to TG Therapeutics?

Kardigan (NASDAQ:KARD) and TG Therapeutics (NASDAQ:TGTX) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, earnings, analyst recommendations, institutional ownership, risk and valuation.

TG Therapeutics has a net margin of 55.22% compared to Kardigan's net margin of 0.00%. TG Therapeutics' return on equity of 73.49% beat Kardigan's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kardigan	N/A	N/A	N/A
TG Therapeutics	55.22%	73.49%	34.14%

TG Therapeutics has higher revenue and earnings than Kardigan.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kardigan	N/A	N/A	N/A	N/A	N/A
TG Therapeutics	$799.54M	10.54	$447.18M	$2.74	20.08

Kardigan presently has a consensus target price of $42.25, indicating a potential upside of 99.48%. TG Therapeutics has a consensus target price of $63.00, indicating a potential upside of 14.48%. Given Kardigan's stronger consensus rating and higher probable upside, equities analysts clearly believe Kardigan is more favorable than TG Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kardigan	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80
TG Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44

58.6% of TG Therapeutics shares are held by institutional investors. 8.9% of TG Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, TG Therapeutics had 9 more articles in the media than Kardigan. MarketBeat recorded 13 mentions for TG Therapeutics and 4 mentions for Kardigan. TG Therapeutics' average media sentiment score of 1.12 beat Kardigan's score of 0.23 indicating that TG Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kardigan	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
TG Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

TG Therapeutics beats Kardigan on 9 of the 11 factors compared between the two stocks.

How does Kardigan compare to Oruka Therapeutics?

Kardigan (NASDAQ:KARD) and Oruka Therapeutics (NASDAQ:ORKA) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, risk, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.

In the previous week, Oruka Therapeutics had 4 more articles in the media than Kardigan. MarketBeat recorded 8 mentions for Oruka Therapeutics and 4 mentions for Kardigan. Oruka Therapeutics' average media sentiment score of 1.29 beat Kardigan's score of 0.23 indicating that Oruka Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kardigan	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Oruka Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Kardigan presently has a consensus price target of $42.25, indicating a potential upside of 99.48%. Oruka Therapeutics has a consensus price target of $134.30, indicating a potential upside of 35.06%. Given Kardigan's higher probable upside, research analysts plainly believe Kardigan is more favorable than Oruka Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kardigan	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80
Oruka Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kardigan	N/A	N/A	N/A	N/A	N/A
Oruka Therapeutics	N/A	N/A	-$105.43M	-$2.03	N/A

56.4% of Oruka Therapeutics shares are held by institutional investors. 23.5% of Oruka Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Kardigan's return on equity of 0.00% beat Oruka Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kardigan	N/A	N/A	N/A
Oruka Therapeutics	N/A	-21.65%	-20.88%

Summary

Oruka Therapeutics beats Kardigan on 6 of the 9 factors compared between the two stocks.

How does Kardigan compare to CG Oncology?

Kardigan (NASDAQ:KARD) and CG Oncology (NASDAQ:CGON) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, media sentiment, valuation, dividends, risk and profitability.

In the previous week, CG Oncology had 2 more articles in the media than Kardigan. MarketBeat recorded 6 mentions for CG Oncology and 4 mentions for Kardigan. CG Oncology's average media sentiment score of 1.05 beat Kardigan's score of 0.23 indicating that CG Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kardigan	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
CG Oncology	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Kardigan has higher earnings, but lower revenue than CG Oncology.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kardigan	N/A	N/A	N/A	N/A	N/A
CG Oncology	$4.04M	1,720.58	-$160.99M	-$2.69	N/A

26.6% of CG Oncology shares are owned by institutional investors. 4.8% of CG Oncology shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Kardigan currently has a consensus target price of $42.25, suggesting a potential upside of 99.48%. CG Oncology has a consensus target price of $83.18, suggesting a potential upside of 6.07%. Given Kardigan's stronger consensus rating and higher possible upside, equities research analysts plainly believe Kardigan is more favorable than CG Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kardigan	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80
CG Oncology	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71

Kardigan has a net margin of 0.00% compared to CG Oncology's net margin of -3,602.68%. Kardigan's return on equity of 0.00% beat CG Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kardigan	N/A	N/A	N/A
CG Oncology	-3,602.68%	-25.20%	-23.98%

Summary

CG Oncology beats Kardigan on 6 of the 11 factors compared between the two stocks.

Get Kardigan News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KARD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KARD vs. The Competition

Export

Metric	Kardigan	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.96B	$4.06B	$7.40B	$12.81B
Dividend Yield	N/A	3.61%	2.53%	11.02%
P/E Ratio	N/A	11.42	272.19	24.12
Price / Sales	N/A	1,369.91	631.76	95.32
Price / Cash	N/A	108.37	79.89	53.65
Price / Book	N/A	16.88	13.14	6.20
Net Income	N/A	-$22.76M	$3.47B	$348.07M
7 Day Performance	-3.77%	1.55%	1.38%	0.67%
1 Month Performance	2.12%	11.70%	8.62%	4.84%
1 Year Performance	N/A	56.88%	25.90%	16.83%

Kardigan Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KARD Kardigan	3.8487 of 5 stars	$21.18 +1.2%	$42.25 +99.5%	N/A	$1.96B	N/A	N/A	N/A	News Coverage Analyst Forecast
IBRX ImmunityBio	2.3763 of 5 stars	$7.57 -1.0%	$14.20 +87.6%	+264.0%	$8.11B	$113.29M	N/A	590
RYTM Rhythm Pharmaceuticals	2.91 of 5 stars	$115.48 -0.5%	$142.44 +23.3%	+14.3%	$7.95B	$239.92M	N/A	140	Positive News
TGTX TG Therapeutics	3.468 of 5 stars	$48.74 +1.7%	$63.00 +29.3%	+94.3%	$7.34B	$799.54M	17.79	290	Positive News
ORKA Oruka Therapeutics	2.8862 of 5 stars	$111.04 +2.7%	$134.30 +20.9%	+601.7%	$7.16B	N/A	N/A	N/A	News Coverage Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KARD) was last updated on 8/26/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Kardigan (KARD) Competitors

KARD vs. IBRX, RYTM, TGTX, ORKA, and CGON

How does Kardigan compare to ImmunityBio?

Summary

How does Kardigan compare to Rhythm Pharmaceuticals?

Summary

How does Kardigan compare to TG Therapeutics?

Summary

How does Kardigan compare to Oruka Therapeutics?

Summary

How does Kardigan compare to CG Oncology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KARD vs. The Competition

Kardigan Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Kardigan (KARD) Competitors

KARD vs. IBRX, RYTM, TGTX, ORKA, and CGON

How does Kardigan compare to ImmunityBio?

Which has preferable valuation & earnings, IBRX or KARD?

Do insiders & institutionals have more ownership in IBRX or KARD?

Does the media favor IBRX or KARD?

Is IBRX or KARD more profitable?

Do analysts prefer IBRX or KARD?

Summary

How does Kardigan compare to Rhythm Pharmaceuticals?

Do analysts recommend RYTM or KARD?

Does the media prefer RYTM or KARD?

Is RYTM or KARD more profitable?

Which has stronger valuation & earnings, RYTM or KARD?

Summary

How does Kardigan compare to TG Therapeutics?

Is KARD or TGTX more profitable?

Which has preferable earnings and valuation, KARD or TGTX?

Do analysts recommend KARD or TGTX?

Do insiders & institutionals believe in KARD or TGTX?

Does the media refer more to KARD or TGTX?

Summary

How does Kardigan compare to Oruka Therapeutics?

Does the media favor KARD or ORKA?

Do analysts prefer KARD or ORKA?

Which has higher valuation & earnings, KARD or ORKA?

Do institutionals and insiders believe in KARD or ORKA?

Is KARD or ORKA more profitable?

Summary

How does Kardigan compare to CG Oncology?

Does the media prefer KARD or CGON?

Which has preferable earnings and valuation, KARD or CGON?

Do insiders & institutionals have more ownership in KARD or CGON?

Do analysts recommend KARD or CGON?

Is KARD or CGON more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KARD vs. The Competition

Kardigan Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools